2 results
Approved WMOCompleted
Primary Objective: The primary objective of this prospective clinical trial is to determine the pharmacokinetic variability of SXT (960 mg) in patients receiving TB treatment. With these pharmacokinetic parameters, a population model and limited…
Approved WMOCompleted
Primary Objective:To demonstrate noninferiority of ACRYSOF IQ PanOptix presbyopia-correcting IOL Model TFNT00 to the AT LISA tri IOL Model 839MP in mean photopic binocular uncorrected intermediate (60 cm) visual acuity at Visit 4A.Secondary…